VGXI Begins Expansion at Woodlands, Texas, Production Center
02/23/2018
According to company officials, once completed the project will increase the company’s footprint by 17% and its cGMP manufacturing space by over 70%.
The upcoming development will add two new flexible-use GMP production areas to serve clients with both large and small scale needs, and a range of products from DNA vaccines to plasmid raw material for GMP viral vector production.
“With three key approvals in 2017 for CAR-T and AAV therapies, the gene therapy industry is rapidly maturing,” said VGXI’s President & CEO, Young Park. “We are excited to support the needs of our growing client base with increased flexibility and capacity across all service levels from Pre-Clinical to Highly Documented (HD) and cGMP grade plasmid production.”
VGXI, a wholly-owned subsidiary CMO of South Korea-based GeneOne Life Science, Inc., was founded in 1997 and has been operating as a GMP plasmid contract manufacturing organization since 2004. Over the 15 year period, the company said it has continued to grow in response to an increasing demand for high quality DNA, with its most recent expansion completed in 2016.
Project Announcements
Eastman Plans Longview, Texas, Production Operations
03/27/2024
DHL Supply Chain-Vantage Data Centers NV11 Plan Nevada Operations
03/26/2024
Big Jet Expands Pittsburgh, Pennsylvania, Operations
03/26/2024
Landmark Ceramics UST Expands Mt. Pleasant, Tennessee, Operations
03/25/2024
Google Plans Cedar Rapids, Iowa, Data Center
03/25/2024
Canada-Based Premier Tech Establishes Williamsport, Pennsylvania, Operations
03/25/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The Logistics Analysis That Drives Industrial Site Selection
Q4 2023
-
Manufacturing Momentum Is Building
Q1 2024
-
Technology’s Influence on Workforce Development
Workforce Q4 2023
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
Industry in the Era of the Electron
Q1 2024